<SEC-DOCUMENT>0001004878-11-000421.txt : 20111206
<SEC-HEADER>0001004878-11-000421.hdr.sgml : 20111206
<ACCEPTANCE-DATETIME>20111205182752
ACCESSION NUMBER:		0001004878-11-000421
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20111205
ITEM INFORMATION:		Termination of a Material Definitive Agreement
FILED AS OF DATE:		20111206
DATE AS OF CHANGE:		20111205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		111244108

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8ktermatmdec11.txt
<DESCRIPTION>8-K RE TERMINATE ATM
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

             Date of Report (date of earliest event reported): December 5, 2011


                               CEL-SCI CORPORATION
                     -------------------------------------
             (Exact name of Registrant as specified in its charter)



      Colorado                        0-11503                 84-0916344
--------------------            --------------------    ----------------------
(State or other jurisdiction    (Commission File No.)     (IRS Employer
of incorporation)                                       Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
               -------------------------------------------------
          (Address of principal executive offices, including Zip Code)



Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                         -----------------------------
          (Former name or former address if changed since last report)


<PAGE>


Item 1.02   Termination of a Material Definitive Agreement


    On December 9, 2010 CEL-SCI Corporation (CEL-SCI) entered into an At the
Market Issuance Agreement with McNicoll Lewis & Vlak LLC, or MLV, under which
CEL-SCI may offer and sell shares of its common stock, having an aggregate
offering price of up to $30,000,000 million from time to time through MLV acting
as agent and/or principal.

      On December 5, 2011 CEL-SCI, per the terms of the agreement, CEL-SCI
exercised its right to terminate the agreement.



                                       2
<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  December 5, 2011             CEL-SCI CORPORATION



                                    By: /s/ Patricia Prichep
                                        -------------------------------------
                                        Patricia Prichep, Senior Vice President
                                         of Operations










                                       3
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
